Expertise in
36
conditions

Dr. Preston Steen

Internal Medicine
Sanford Clinic North
820 4th St N, 
Fargo, ND 
Clinical Trials:Currently Recruiting for 6 Trials
Expertise in
36
conditions
Sanford Clinic North
820 4th St N, 
Fargo, ND 

Overview

Preston Steen is an Internal Medicine provider practicing medicine in Fargo, North Dakota.

Dr. Steen is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Tissue Biopsy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 172 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in ND

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthPartners
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO

Locations

Sanford Clinic North
820 4th St N, Fargo, ND 58102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

140 Clinical Trials

A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Enrollment Status: Recruiting
Publish Date: April 16, 2026
Intervention Type: Procedure, Drug, Radiation, Biological
Study Drugs: Carboplatin, Cisplatin, Pembrolizumab
Study Phase: Phase 2
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug, Other
Study Phase: Phase 3
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium
Study Phase: Phase 3
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Drug, Procedure
Study Drug: Olaparib
Study Phase: Phase 2
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial
Enrollment Status: Recruiting
Publish Date: April 15, 2026
Intervention Type: Procedure, Radiation, Drug
Study Drug: Atezolizumab
Study Phase: Phase 2/Phase 3
Implementation and Effectiveness Trial of HN-STAR
Implementation and Effectiveness Trial of HN-STAR
Enrollment Status: Active_not_recruiting
Publish Date: April 15, 2026
Intervention Type: Other
Study Phase: Not Applicable
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: April 14, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
View 4 Less Clinical Trials

11 Total Publications

Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.
Improving Rural Clinical Trial Enrollment: Recommendations From the Rural Health Working Group of the Alliance Clinical Trials Network.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 27, 2024
Similar Doctors
Expertise in
20
conditions
Dr. Michael Sheldon
Internal Medicine
Expertise in
20
conditions
Dr. Michael Sheldon
Internal Medicine

Essentia Health-South University Clinic (Fargo)

1702 University Dr S, 
Fargo, ND 
 (1.7 miles away)
701-205-0094
Languages Spoken:
English
See accepted insurances

Michael Sheldon is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Sheldon is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Glucocorticoid-Remediable Aldosteronism, Hypertension, Familial Hypertension, and Maturity Onset Diabetes of the Young.

Expertise in
17
conditions
Dr. Kirsten Juhl
Internal Medicine
Expertise in
17
conditions
Dr. Kirsten Juhl
Internal Medicine

Sanford Clinic North

737 Broadway N, 
Fargo, ND 
 (0.5 miles away)
701-234-2261
Languages Spoken:
English
See accepted insurances

Kirsten Juhl is a primary care provider, practicing in Internal Medicine in Fargo, North Dakota. Dr. Juhl is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Bronchiectasis, Seasonal Affective Disorder (SAD), Lung Metastases, and Colorectal Cancer.

Expertise in
8
conditions
Dr. Lakshmi Pathak
Internal Medicine
Expertise in
8
conditions
Dr. Lakshmi Pathak
Internal Medicine

Office

736 Broadway N, 
Fargo, ND 
 (0.5 miles away)
701-234-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lakshmi Pathak is an Internal Medicine provider practicing medicine in Fargo, North Dakota. Dr. Pathak is highly rated in 8 conditions, according to our data. His clinical expertise encompasses End-Stage Renal Disease (ESRD), Diabetic Nephropathy, Chronic Kidney Disease, and Minimal Change Disease.

Frequently Asked Questions about Dr. Preston Steen

How do I make an appointment with Dr. Preston Steen?

You can book an appointment with Dr. Preston Steen by calling their office at 320-839-2502. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Preston Steen a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Preston Steen is classified as an Distinguished expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Preston Steen specialize in?

While Dr. Preston Steen is a Internal Medicine, they have specific expertise in Colorectal Cancer, Lung Adenocarcinoma, and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Preston Steen participate in research or clinical trials?

Yes. Dr. Preston Steen has published 11 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Preston Steen's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Preston Steen accept my insurance?

Dr. Preston Steen accepts most major insurance plans, including HealthPartners and Medica. We recommend calling the office directly at 320-839-2502 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Steen's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 29 Advanced Conditions
    View All 102 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile